Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
RLYB compared with VYNE: revenue, margins and what each company keeps, and the suppliers and customers both name
RLYB
Rallybio Corp
Change
Mkt cap
Revenue
Revenue
VYNE
VYNE Therapeutics Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
RLYB
Rallybio Corp
vs
VYNE
VYNE Therapeutics Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Supply-chain overlap
Desk
News
Calendar
Saved
Search
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only RLYB
9
JNJ
Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. ("J&J")
customer
RXRX
Recursion
customer
SNY
Kymab Limited (Sanofi)
supplier
ABCL
AbCellera Biologics
supplier
5 more · RLYB chain
›
Shared
0
No disclosed counterparties: VYNE.
Only VYNE
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
RLYB
Rallybio Corp
Change
15.85
▲
+0.57%
Mkt cap
$84.9M
Revenue
$212,000
Q1 FY26
Revenue
$858,000
FY25
VYNE
VYNE Therapeutics Inc.
Change
17.09
▼
−4.70%
Regular session
Nov 3 '26
Mkt cap
—
Revenue
—
Revenue
—
vs
Compare
Regular session
Nov 3 '26
RLYB
Rallybio Corp
vs
VYNE
VYNE Therapeutics Inc.
15.85
▲
+0.57%
Price
17.09
▼
−4.70%
$84.9M
Mkt cap
—
Q1 FY26
$212,000
Revenue
—
FY25
$858,000
Revenue
—
Change
Change
RLYB
15.85
▲
+0.57%
vs
VYNE
17.09
▼
−4.70%
Regular session
Nov 3 '26